The drug-free outcome
Patients in the active group consumed roughly half the opioids over the first 48 hours. The study design makes a placebo explanation hard to sustain.
TL;DR
In Rhode et al. (2010), the active tPEMF group consumed roughly half the narcotics over the first 48 hours — about 5 oxycodone-equivalent pills versus 11 in the sham group (p = 0.002). This is the result that matters most for long-term outcomes: how much medication a patient uses in the first two days strongly predicts dependence risk.
Rhode et al. (2010) tracked total narcotic consumption over the first 48 hours. The active group consumed approximately 5 oxycodone-equivalent pills; the sham group consumed approximately 11 — a 2.2-fold difference, with p = 0.002. Both groups had identical access to pain medication; the difference was driven by reduced need, not rationing.
Research consistently shows that the quantity of opioids prescribed and consumed in the immediate post-surgical period is one of the strongest predictors of long-term opioid use. A patient who takes 5 pills rather than 11 is not simply less comfortable for 48 hours — they are meaningfully less likely to become a chronic user. The prescription opioid pipeline begins here, at discharge, with a patient in pain who has no alternative.
Fewer opioids in the first 48 hours means less nausea (a primary opioid side effect), clearer cognition, better mobility, and a faster path to physical therapy. It also means a shorter prescription — and a smaller quantity of pills in the home, which has household-level safety implications. The 2.2× reduction is not a comfort metric. It is an outcome metric with downstream consequences that extend well past discharge.
The 2.2× narcotic reduction was a pre-specified primary endpoint of Rhode 2010, not a post-hoc finding. Opioid consumption was tracked as morphine milligram equivalents, standardized across the different narcotic agents patients might use. Both groups had identical access — the same analgesic options, the same nursing staff, the same post-operative environment. The difference between 5 and 11 pills is therefore entirely attributable to reduced analgesic need in the active group, not to rationing or protocol differences. The p-value of 0.002 represents a less than 0.2% probability of seeing a difference this large by chance.
Multimodal analgesia — combining NSAIDs, acetaminophen, and opioids as needed — is the current gold standard for post-operative pain management. The Rhode 2010 active group was already receiving multimodal care; the 2.2× reduction is the incremental opioid-sparing effect of adding tPEMF to that protocol. Nerve blocks (femoral, adductor canal, brachial plexus) are the other major opioid-sparing intervention in surgical anesthesia, but they are indication-specific, require anesthesiology involvement, and are not available for home use post-discharge. tPEMF continues to work after the block wears off and does not require any clinical interaction to administer.
Sources & references
Related